429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma
oleh: Antoni Ribas, Olivier Michielin, Reinhard Dummer, Scott Diede, Salvador Martin-Algarra, Sheryl Treichel, Edward Chan
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2020-11-01 |
Deskripsi
No description available for this item.